Clinical trial
Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)
NCT00416884 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)
- Lead sponsor
- OHSU Knight Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 31, 2003
- Completion date
- March 31, 2008
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.